These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37109127)

  • 1. Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE).
    Chen D; Untaru R; Stavropoulou G; Assadi-Khansari B; Kelly C; Croft AJ; Sugito S; Collins NJ; Sverdlov AL; Ngo DTM
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2.
    Somuncu MU; Kalayci B; Avci A; Akgun T; Karakurt H; Demir AR; Avci Y; Can M
    Horm Mol Biol Clin Investig; 2020 Feb; 41(2):. PubMed ID: 32112700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of soluble ST2 in acute coronary syndrome with diabetes.
    Jha D; Goenka L; Ramamoorthy T; Sharma M; Dhandapani VE; George M
    Eur J Clin Invest; 2018 Sep; 48(9):e12994. PubMed ID: 29992539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic changes in soluble suppression of tumorigenicity 2 levels predict major adverse cardiovascular events in patients with ST‑segment elevation myocardial infarction.
    Liu L; Li S; Ding X; Wang D; Li W; Li H
    Pol Arch Intern Med; 2022 Oct; 132(10):. PubMed ID: 35984957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive value of neutrophil/lymphocyte ratio combined with soluble growth stimulating expression gene 2 protein on the occurrence of in-hospital major adverse cardiaovascular events in patients with myocardial injury from moderate-severe acute carbon monoxide poisoning: a single-center prospective observational study].
    Liu Q; Xiao Q; Han Y; Liu Y; Li W; Gao X; Zhu B; Wang W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1088-1093. PubMed ID: 34839867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.
    Pfetsch V; Sanin V; Jaensch A; Dallmeier D; Mons U; Brenner H; Koenig W; Rothenbacher D
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):167-177. PubMed ID: 28283847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role of High-sensitivity Cardiac Troponin I and Soluble Suppression of Tumorigenicity-2 in Surgical Intensive Care Unit Patients Undergoing Non-cardiac Surgery.
    Yang HS; Hur M; Yi A; Kim H; Kim J
    Ann Lab Med; 2018 May; 38(3):204-211. PubMed ID: 29401554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community.
    Watson CJ; Tea I; O'Connell E; Glezeva N; Zhou S; James S; Gallagher J; Snider J; Januzzi JL; Ledwidge MT; McDonald KM
    J Cell Mol Med; 2020 Jun; 24(11):6495-6499. PubMed ID: 32347644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble ST2 for predicting heart failure, atrial fibrillation and death in patients with coronary heart disease with or without renal insufficiency.
    Li H; Zhu Q; Bai J; Chen J; Zhu Z; Hao B; Wang W; Bai Y; Liu H
    Heliyon; 2024 May; 10(9):e29804. PubMed ID: 38698979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of high-sensitivity ST2 and NT-proBNP for predicting major adverse cardiovascular events in coronary heart failure.
    Bai J; Han L; Liu H
    Ann Palliat Med; 2020 Jul; 9(4):1976-1989. PubMed ID: 32762223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sST2 level is an independent influencing factor associated with atrial fibrillation in heart failure patients: a case-control study.
    Yan X; Guo Y; Li L; Wang Z; Li Z
    J Thorac Dis; 2022 May; 14(5):1578-1587. PubMed ID: 35693622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation.
    Krittayaphong R; Pumprueg S; Sairat P
    Clin Cardiol; 2022 Apr; 45(4):447-456. PubMed ID: 35188278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation.
    Vílchez JA; Pérez-Cuellar M; Marín F; Gallego P; Manzano-Fernández S; Valdés M; Vicente V; Noguera-Velasco JA; Lip GY; Ordóñez-Llanos J; Roldán V
    Eur J Clin Invest; 2015 Sep; 45(9):899-905. PubMed ID: 26081996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure.
    Gül İ; Yücel O; Zararsız A; Demirpençe Ö; Yücel H; Zorlu A; Yılmaz MB
    Anatol J Cardiol; 2017 Sep; 18(3):200-205. PubMed ID: 28761021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis value of serum soluble ST2 level in acute ischemic stroke and STEMI patients in the era of mechanical reperfusion therapy.
    Mechtouff L; Paccalet A; Crola Da Silva C; Buisson M; Mewton N; Amaz C; Bonnefoy-Cudraz E; Leboube S; Cho TH; Nighoghossian N; Ovize M; Bochaton T
    J Neurol; 2022 May; 269(5):2641-2648. PubMed ID: 34694426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ST2 for Prediction of Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary PCI.
    Liu X; Hu Y; Huang W; Zhang G; Cao S; Yan X; Li L; Zhang L; Zheng X
    Int Heart J; 2019 Jan; 60(1):19-26. PubMed ID: 30464124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.
    Polovina M; Đikić D; Vlajković A; Vilotijević M; Milinković I; Ašanin M; Ostojić M; Coats AJS; Seferović PM
    Int J Cardiol; 2017 Dec; 249():191-197. PubMed ID: 28986061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Ma X; Shao Q; Dong L; Cheng Y; Lv S; Shen H; Liang J; Wang Z; Zhou Y
    Medicine (Baltimore); 2020 Jul; 99(30):e21321. PubMed ID: 32791726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation.
    Ma X; Yuan H; Luan HX; Shi YL; Zeng XL; Wang Y
    Clin Chim Acta; 2018 May; 480():138-142. PubMed ID: 29428199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention.
    Fukase T; Dohi T; Koike T; Yasuda H; Takeuchi M; Takahashi N; Chikata Y; Endo H; Doi S; Nishiyama H; Okai I; Iwata H; Okazaki S; Miyauchi K; Daida H; Minamino T
    ESC Heart Fail; 2022 Feb; 9(1):545-554. PubMed ID: 34811932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.